CD44 mediates constitutive type I receptor signaling in cervical carcinoma cells

Manja Wobus, Robin Kuns, Claudia Wolf, Lars Christian Horn, Uwe Köhler, Irena Sheyn, Bruce A. Werness, Lawrence (Larry) Sherman

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective. The CD44 transmembrane glycoprotein family has been implicated in the growth and metastasis of numerous human cancers. CD44 may function in some cells through interactions with type I receptor tyrosine kinases, including erbB2. Here, we tested whether CD44 interacts with erbB2 and another type I receptor, the epidermal growth factor receptor (EGFR), in human cervical carcinoma tissues and cell lines and whether these interactions influence erbB2 signaling. Methods. CD44, EGFR, and erbB2 colocalization were examined in 36 pT1b-pT2b cervical cancer cases and in the CaSki and SiHa cervical carcinoma cell lines by immunohistochemistry and laser scanning confocal microscopy. The role of CD44-EGFR-erbB2 interactions in erbB2 signaling was examined by immunoprecipitation and using antisense CD44 oligonucleotides. Results. CD44, erbB2, and EGFR coexpression and colocalization were observed in 42% (15/36) of cervical carcinoma cases and in both cervical carcinoma cell lines. Colocalization occurred to an equivalent extent in all tumor grades examined. CD44 coimmunoprecipitated with erbB2 and EGFR in cervical carcinoma cell lysates, indicating that these proteins interact with each other. Reduction of CD44 expression inhibited constitutive erbB2 activity. High CD44 expression was linked to EGFR activity using dominant negative EGFR, suggesting that type I receptors may autoregulate their activity in these cells. Conclusions. Our data indicate that CD44 can mediate type I receptor function in cervical carcinoma cells that overexpress both CD44 and either erbB2 or EGFR and suggest a novel mechanism by which these proteins may contribute to cervical carcinoma tumor growth and metastasis.

Original languageEnglish (US)
Pages (from-to)227-234
Number of pages8
JournalGynecologic Oncology
Volume83
Issue number2
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Carcinoma
Cell Line
Neoplasm Metastasis
Neoplasms
Antisense Oligonucleotides
Receptor Protein-Tyrosine Kinases
Growth
Immunoprecipitation
Confocal Microscopy
Cell Communication
Uterine Cervical Neoplasms
Glycoproteins
Proteins
Immunohistochemistry

Keywords

  • CD44
  • Cervical carcinoma
  • erbB2

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

CD44 mediates constitutive type I receptor signaling in cervical carcinoma cells. / Wobus, Manja; Kuns, Robin; Wolf, Claudia; Horn, Lars Christian; Köhler, Uwe; Sheyn, Irena; Werness, Bruce A.; Sherman, Lawrence (Larry).

In: Gynecologic Oncology, Vol. 83, No. 2, 2001, p. 227-234.

Research output: Contribution to journalArticle

Wobus, M, Kuns, R, Wolf, C, Horn, LC, Köhler, U, Sheyn, I, Werness, BA & Sherman, LL 2001, 'CD44 mediates constitutive type I receptor signaling in cervical carcinoma cells', Gynecologic Oncology, vol. 83, no. 2, pp. 227-234. https://doi.org/10.1006/gyno.2001.6369
Wobus, Manja ; Kuns, Robin ; Wolf, Claudia ; Horn, Lars Christian ; Köhler, Uwe ; Sheyn, Irena ; Werness, Bruce A. ; Sherman, Lawrence (Larry). / CD44 mediates constitutive type I receptor signaling in cervical carcinoma cells. In: Gynecologic Oncology. 2001 ; Vol. 83, No. 2. pp. 227-234.
@article{a526130d18634dc282472e27b53ade1b,
title = "CD44 mediates constitutive type I receptor signaling in cervical carcinoma cells",
abstract = "Objective. The CD44 transmembrane glycoprotein family has been implicated in the growth and metastasis of numerous human cancers. CD44 may function in some cells through interactions with type I receptor tyrosine kinases, including erbB2. Here, we tested whether CD44 interacts with erbB2 and another type I receptor, the epidermal growth factor receptor (EGFR), in human cervical carcinoma tissues and cell lines and whether these interactions influence erbB2 signaling. Methods. CD44, EGFR, and erbB2 colocalization were examined in 36 pT1b-pT2b cervical cancer cases and in the CaSki and SiHa cervical carcinoma cell lines by immunohistochemistry and laser scanning confocal microscopy. The role of CD44-EGFR-erbB2 interactions in erbB2 signaling was examined by immunoprecipitation and using antisense CD44 oligonucleotides. Results. CD44, erbB2, and EGFR coexpression and colocalization were observed in 42{\%} (15/36) of cervical carcinoma cases and in both cervical carcinoma cell lines. Colocalization occurred to an equivalent extent in all tumor grades examined. CD44 coimmunoprecipitated with erbB2 and EGFR in cervical carcinoma cell lysates, indicating that these proteins interact with each other. Reduction of CD44 expression inhibited constitutive erbB2 activity. High CD44 expression was linked to EGFR activity using dominant negative EGFR, suggesting that type I receptors may autoregulate their activity in these cells. Conclusions. Our data indicate that CD44 can mediate type I receptor function in cervical carcinoma cells that overexpress both CD44 and either erbB2 or EGFR and suggest a novel mechanism by which these proteins may contribute to cervical carcinoma tumor growth and metastasis.",
keywords = "CD44, Cervical carcinoma, erbB2",
author = "Manja Wobus and Robin Kuns and Claudia Wolf and Horn, {Lars Christian} and Uwe K{\"o}hler and Irena Sheyn and Werness, {Bruce A.} and Sherman, {Lawrence (Larry)}",
year = "2001",
doi = "10.1006/gyno.2001.6369",
language = "English (US)",
volume = "83",
pages = "227--234",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - CD44 mediates constitutive type I receptor signaling in cervical carcinoma cells

AU - Wobus, Manja

AU - Kuns, Robin

AU - Wolf, Claudia

AU - Horn, Lars Christian

AU - Köhler, Uwe

AU - Sheyn, Irena

AU - Werness, Bruce A.

AU - Sherman, Lawrence (Larry)

PY - 2001

Y1 - 2001

N2 - Objective. The CD44 transmembrane glycoprotein family has been implicated in the growth and metastasis of numerous human cancers. CD44 may function in some cells through interactions with type I receptor tyrosine kinases, including erbB2. Here, we tested whether CD44 interacts with erbB2 and another type I receptor, the epidermal growth factor receptor (EGFR), in human cervical carcinoma tissues and cell lines and whether these interactions influence erbB2 signaling. Methods. CD44, EGFR, and erbB2 colocalization were examined in 36 pT1b-pT2b cervical cancer cases and in the CaSki and SiHa cervical carcinoma cell lines by immunohistochemistry and laser scanning confocal microscopy. The role of CD44-EGFR-erbB2 interactions in erbB2 signaling was examined by immunoprecipitation and using antisense CD44 oligonucleotides. Results. CD44, erbB2, and EGFR coexpression and colocalization were observed in 42% (15/36) of cervical carcinoma cases and in both cervical carcinoma cell lines. Colocalization occurred to an equivalent extent in all tumor grades examined. CD44 coimmunoprecipitated with erbB2 and EGFR in cervical carcinoma cell lysates, indicating that these proteins interact with each other. Reduction of CD44 expression inhibited constitutive erbB2 activity. High CD44 expression was linked to EGFR activity using dominant negative EGFR, suggesting that type I receptors may autoregulate their activity in these cells. Conclusions. Our data indicate that CD44 can mediate type I receptor function in cervical carcinoma cells that overexpress both CD44 and either erbB2 or EGFR and suggest a novel mechanism by which these proteins may contribute to cervical carcinoma tumor growth and metastasis.

AB - Objective. The CD44 transmembrane glycoprotein family has been implicated in the growth and metastasis of numerous human cancers. CD44 may function in some cells through interactions with type I receptor tyrosine kinases, including erbB2. Here, we tested whether CD44 interacts with erbB2 and another type I receptor, the epidermal growth factor receptor (EGFR), in human cervical carcinoma tissues and cell lines and whether these interactions influence erbB2 signaling. Methods. CD44, EGFR, and erbB2 colocalization were examined in 36 pT1b-pT2b cervical cancer cases and in the CaSki and SiHa cervical carcinoma cell lines by immunohistochemistry and laser scanning confocal microscopy. The role of CD44-EGFR-erbB2 interactions in erbB2 signaling was examined by immunoprecipitation and using antisense CD44 oligonucleotides. Results. CD44, erbB2, and EGFR coexpression and colocalization were observed in 42% (15/36) of cervical carcinoma cases and in both cervical carcinoma cell lines. Colocalization occurred to an equivalent extent in all tumor grades examined. CD44 coimmunoprecipitated with erbB2 and EGFR in cervical carcinoma cell lysates, indicating that these proteins interact with each other. Reduction of CD44 expression inhibited constitutive erbB2 activity. High CD44 expression was linked to EGFR activity using dominant negative EGFR, suggesting that type I receptors may autoregulate their activity in these cells. Conclusions. Our data indicate that CD44 can mediate type I receptor function in cervical carcinoma cells that overexpress both CD44 and either erbB2 or EGFR and suggest a novel mechanism by which these proteins may contribute to cervical carcinoma tumor growth and metastasis.

KW - CD44

KW - Cervical carcinoma

KW - erbB2

UR - http://www.scopus.com/inward/record.url?scp=0034763605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034763605&partnerID=8YFLogxK

U2 - 10.1006/gyno.2001.6369

DO - 10.1006/gyno.2001.6369

M3 - Article

C2 - 11606076

AN - SCOPUS:0034763605

VL - 83

SP - 227

EP - 234

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -